Research & Development
Fragile X Syndrome
Real-world study: Genetic testing appears underused in autism
Neurological medicine researchers evaluated how frequently chromosomal microarray (CMA) and fragile X syndrome testing were conducted in people with autism spectrum disorder through the Rhode Island Consortium for Autism Research and Treatment (RI-CART). Results were reported by Dr. Eric Morrow, PhD, head of the Developmental Disorders Genetics Research Program at Brown University, and colleagues in a research letter.
May 13, 2020
FDA clears 1st fragile X test: Asuragen's AmplideX
Fragile X syndrome is a genetic condition that results in developmental delays and intellectual disability. Asuragen's AmplideX fragile X Dx and carrier screen kit screens blood and shows the number of repeats of the CGG segment in the FMR1 gene associated with the condition.
February 20, 2020
Lineagen reports high accuracy for fragile X genetic test
The Salt Lake City-based company specializes in genetic testing for autism spectrum disorder and other conditions associated with developmental delays.
October 28, 2019
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Quest Diagnostics offers suite of services for transplant patients and living donors
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Rapid nirmatrelvir treatment in study reduced long-COVID risk
Page 1 of 1